- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01839929
A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF (PeACE)
April 30, 2013 updated by: Astellas Pharma Korea, Inc.
A Multicenter, Open-label, Single-arm, Non-inferiority Study to Assess the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF® in Stable Kidney Transplant Patients Converted From a PROGRAF® Based Immunosuppressive Regimen
The purpose of this study is to evaluate the efficacy of tacrolimus modified release formulation Advagraf® after conversion from Prograf® in stable kidney transplant patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
138
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Busan, Korea, Republic of
-
Daegu, Korea, Republic of
-
Daejeon, Korea, Republic of
-
Seoul, Korea, Republic of
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients received a kidney transplant at least 12 months ago prior to enrollment.
- Patients have taken unchanged dosage of Prograf® and remained stable serum level of tacrolimus at least for 12 weeks prior to enrollment.
- Patients have kept in unchanged immunosuppressive therapy (combination therapy) at least for 12 weeks prior to enrollment.
- Female patients of childbearing potential must have a negative urine or serum pregnancy test prior to enrollment, and agreed to the deliberate prevention of conception during the trial.
- Patients are considered clinically stable by observer's judgment.
- Patients must understand the purpose and risk of participating the trial and signed on the written consent.
Exclusion Criteria:
- Patients have previously received an organ transplant other than a kidney.
- Patients have had acute transplant rejection within 12 weeks, or acute transplant rejection requiring antilymphocyte therapy within 24 weeks prior to enrollment.
- Patients newly diagnosed malignant tumors after organ transplant but the patients treated completely with basal or squamous cell carcinoma of the skin are excepted.
- Patients have a known hypersensitivity to Prograf® or tacrolimus.
- Patients whose medical condition are able to interfere with the study objectives.
- Patients who are at the risk of drug abuse or mental disorders or communicate difficulties with the observer.
- Patients have been participated in another clinical trial, or treated with drugs of clinical trial within 28 days prior to enrollment.
- Patients have been taken prohibited combination agents within 28 days prior to enrollment.
- Patients are pregnant or lactating.
- Patient are HIV-positive.
- Patients are not able to keep the scheduled visit.
- Patients whose GFR (MDRD) is in the level of <30 mL/min.
- Patients who are at the condition of 'Creeping creatinine (defined by 20% increase within 6 months prior to enrollment)
- Patients whose SGPT/AST and/or SGOT/ALT levels have been elevated greater than 2 times the upper value of the normal range.
- Patients have FSGS or MPGN Type II as underlying diseases.
- Patients are with cirrhosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Prograf/Advagraf
conversion from Prograf to Advagraf
|
oral
Other Names:
oral
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in glomerular filtration rate (GFR) at Week 24 from baseline
Time Frame: Baseline and Week-24
|
Baseline and Week-24
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Blood Pressure (BP) at Week 24 from baseline
Time Frame: Baseline and Week-24
|
Baseline and Week-24
|
Change in HbA1c at Week 24 from baseline
Time Frame: Baseline and Week-24
|
Baseline and Week-24
|
Change in tacrolimus blood trough level at Week 24 from baseline
Time Frame: Baseline and Week-24
|
Baseline and Week-24
|
Safety assessed by the incidence of adverse events, physical exam., vital signs and labo tests
Time Frame: For 24 weeks
|
For 24 weeks
|
Overall frequency of acute rejection
Time Frame: For 24 weeks
|
For 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2010
Primary Completion (ACTUAL)
February 1, 2013
Study Completion (ACTUAL)
February 1, 2013
Study Registration Dates
First Submitted
April 23, 2013
First Submitted That Met QC Criteria
April 23, 2013
First Posted (ESTIMATE)
April 25, 2013
Study Record Updates
Last Update Posted (ESTIMATE)
May 1, 2013
Last Update Submitted That Met QC Criteria
April 30, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ADV-KT-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Bristol-Myers SquibbCompletedKidney Transplantation: Transplantation, Kidney
-
Nantes University HospitalTerminated
-
Hospices Civils de LyonCompletedKidney Transplantation | Pancreas-kidney TransplantationFrance
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
The Hospital for Sick ChildrenCompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCanada
-
Astellas Pharma Europe Ltd.TerminatedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationSpain, Australia, France, Germany, Canada, Italy, United Kingdom, Belgium, South Africa, Switzerland, Sweden, United States, Austria, Brazil, Czechia, Denmark, Finland, Hungary, Ireland, Mexico, Netherlands, New Zealand, Poland
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationBelgium, France, Germany, Poland, Spain, United Kingdom
-
Medical University of ViennaUnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on Prograf
-
University Medicine GreifswaldCompletedHypercholesterolemia | Pharmacokinetics | Immunosuppression | Drug InteractionsGermany
-
Uji Takeda HospitalNot yet recruitingSurgical Site Infection
-
National Taiwan University HospitalAstellas Pharma Taiwan, Inc.UnknownAdherence to Medication RegimeTaiwan
-
Veloxis PharmaceuticalsCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
-
Astellas Pharma IncCompleted
-
Veloxis PharmaceuticalsCompleted
-
HK inno.N CorporationNot yet recruitingHealthyKorea, Republic of
-
University of British ColumbiaSimon Fraser University; Astellas Pharma Canada, Inc.CompletedRenal Transplant | Renal DiseaseCanada